NCT02110342View on ClinicalTrials.gov

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Healthy
Interventions
DRUG

[14C] PF-04449913

Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913

Trial Locations (1)

53704

Pfizer Investigational Site, Madison

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02110342 - A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body | Biotech Hunter | Biotech Hunter